Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

Table 3 Univariate and multivariate analyses of prognostic factors for predicting overall survival and time to progression

Variable	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
OS
Child-Pugh, class B	1.446 (1.044-1.547)	0.039	1.321 (1.112-1.711)	0.021
AFP > 400 ng/mL	1.651 (1.351-1.782)	0.021	1.446 (0.875-1.836)	0.239
PIVKA > 40 mAU/mL	1.324 (1.023-1.472)	0.043	1.568 (0.411-1.687)	0.085
PVTT, yes	2.145 (1.897-3.587)	0.003	3.125 (3.015-3.568)	0.008
Extrahepatic metastasis, yes	1.784 (1.254-2.571)	0.013	2.871 (2.581-3.052)	0.028
Cutaneous toxic effects, yes	0.741 (0.654-0.968)	0.025	0.845 (0.425-1.751)	0.129
Hypothyroidism, yes	0.623 (0.487-0.912)	0.034	0.641 (0.489-0.901)	0.017
TTP
AFP > 400 ng/mL	1.757 (1.271-1.972)	0.023	1.872 (1.357-2.135)	0.017
PVTT, yes	2.595 (1.377-3.889)	0.003	2.472 (2.243-2.891)	0.008
Extrahepatic metastasis, yes	1.536 (1.296-1.765)	0.031	1.489 (1.246-1.574)	0.012
Cutaneous toxic effects, yes	0.874 (0.621-0.925)	0.036	0.785 (0.358-1.258)	0.157
Hypothyroidism, yes	0.741 (0.514-0.870)	0.024	0.613 (0.362-0.886)	0.018

AFP: Alpha fetalprotein; PIVKA: Protein induced by vitamin K absence or antagonist-II; OS: Overall survival; PVTT: Portal vein tumor thrombus; HR: Hazard rate; TTP: Time to progression; CI: Confidence interval.